Strides Arcolab Ltd. said its wholly-owned subsidiary Onco Therapies Ltd. had obtained two more ANDA approvals from US FDA for Fludarabine Phosphate for Injection, USP packaged in 50mg/2 mL, single use vials (25 mg/mL upon reconstitution) - Lyophilized format and Idarubicin Hydrochloride Injection, 1mg/mL -5 mL and 20 mL single dose vials.
Fludarabine is a chemotherapy drug used to treat chronic Lymphocytic leukemia (a type of cancer of the while blood cells) in adults, while Idarubicin belongs to the group of cancer-fighting medications known as antineoplastics and is used alone or in combination with other antineoplastic medications to treat leukemia.
The combined market for the two drugs is around $20 million, the company said.
At the BSE, Strides Arcolab shares are currently trading at Rs.907.00, up 1.16 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.